en · de · es · pt
cjc-1295-notes.peptides3081.com › Blog › Cjc-1295 Background And Mechanism — Worked Examples

Cjc-1295 Background And Mechanism — Worked Examples

By Editorial Desk · published 2026-01-23 · last reviewed 2026-03-17 · Blog

Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-03-17. Where a claim depends on a specific study, the study is described rather than over-claimed.

CJC-1295 Background and Mechanism

Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.

CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.

The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.

Receptor Action and Clearance

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Cjc-1295 at a glance

PropertyValueNotes
Molecular weight (with DAC)~3647 DaCalculated from the full amino acid sequence
Molecular weight (without DAC)~3368 DaMod GRF(1-29) variant
AppearanceWhite lyophilized powderTypical form supplied for research
SolubilitySoluble in waterDissolves in aqueous buffers
Receptor targetGHRH receptorExpressed on pituitary somatotroph cells

Handling Storage And Analytical Methods

Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.

Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.

Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.

Related pages on this site

Receptor Action and Pharmacokinetics

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Persistence, Stability and Measurement

Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.

Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Handling, Stability and Analysis

Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.

Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.

Reference notes

Javits (1952), former ambassador and permanent U.S. representative to the Conference on Disarmament in Geneva 2001–2003; U.S. permanent representative to the Organisation for the Prohibition of Chemical Weapons 2003–2009 James D. Theberge (1952), former U.S. ambassador to Chile and Nicaragua G. Norman Anderson (1954), former U.S. ambassador to Sudan David J. Bardin (1954), deputy administrator of the Federal Energy Administration; commissioner of the New Jersey Department of Environmental Protection William Haddad (1954), political operative, lobbyist, and journalist, Peace Corps founding official, aide to the Kennedy family, and grandson-in-law of Franklin D. Roosevelt Richard E. Benedick (1955), president emeritus of the National Council for Science and the Environment, ambassador, and chief U.S. negotiator to the Montreal Protocol John L. Hirsch (1957), U.S. ambassador to Sierra Leone 1995–1998 Morton Halperin (1958), deputy assistant secretary of defense, director of policy planning for the U.S. State Department, and member of Richard Nixon's Enemies List Shelby Brewer (1959), assistant secretary of energy for nuclear energy 1981–1984 Benjamin Huberman (1959), acting director of the Office of Science and Technology Policy; acting science advisor to the president in 1981 Pat Mullins (1959), chairman of the Republican Party of Virginia Constantine Menges (1960), national security aide to Ronald Reagan James E.

The Blue Book, formally titled Nomenclature of Organic Chemistry, is a collection of recommendations on organic chemical nomenclature. Updates are published at irregular intervals. A full edition was published in 1979, an abridged and updated version of which was published in 1993 as A Guide to IUPAC Nomenclature of Organic Compounds. Both of these are now out-of-print in their paper versions, but are available free of charge in electronic versions. After the release of a draft version for public comment in 2004 and the publication of several revised sections in the journal Pure and Applied Chemistry, a fully revised version was published in print in 2013.

== Uses == TCFH itself is a common reagent used in the preparation of uronium and guanidinium salts used for amide bond formation and peptide synthesis, such as HATU. Amide bond formation with TCFH can be performed in a wide range of organic solvents, most commonly acetonitrile, but also water and in the solid state. Reactions typically require an added Brønsted base, and a wide range can be employed including N,N-diisopropylethylamine (DIPEA). In reactions of carboxylic acids with TCFH and a weakly Lewis basic amine like DIPEA, formation of an acid chloride or anhydride as the active acylating agent occurs. Use of N-methylimidazole (NMI) as a base, with both Brønsted and Lewis basic properties, provides some unique advantages. Reactions of carboxylic acids with TCFH and a strongly Lewis basic amine like NMI lead to in situ formation of an N-acyl imidazolium ion (NAI) as the active acylating agent.

Tyrannosaurus lived during what is referred to as the Lancian faunal stage (Maastrichtian age) at the end of the Late Cretaceous. Tyrannosaurus ranged from Canada in the north to at least New Mexico in the south of Laramidia. Several notable Tyrannosaurus remains have been found in the Hell Creek Formation. During the Maastrichtian this area was maritime to subtropical, with a warm and humid climate. The flora consisted mostly of angiosperms, but also included trees like dawn redwood (Metasequoia). Archosaurs discovered from this formation include the ceratopsians Leptoceratops, Torosaurus, and Triceratops, the hadrosaurid Edmontosaurus annectens, the parksosaurid Thescelosaurus, the ankylosaurs Ankylosaurus and Denversaurus, the pachycephalosaurs Pachycephalosaurus, Platytholus and Sphaerotholus, the paravian theropods Acheroraptor and Pectinodon, other maniraptoran theropods Anzu, Eoneophron, Trierarchuncus and indeterminate ornithomimids, the tyrannosauroid Nanotyrannus, and the azhdarchid pterosaur Infernodrakon.

== Reactivity == As a simple, abundant and bifunctional compound, pyruvic acid has been shown to participate in many reactions. Pyruvate reacts with amino acids to give alanine by the process called transamination:

Sources: en.wikipedia.org

Reference notes

== World War 2 == On 10 June 1940, with Italy's declaration of war on France and the United Kingdom, Calabria became involved in World War II. The civilian population immediately began to suffer from starvation and undernourishment, due to the lack of labor, low wages and inflation. Some foodstuffs were already rationed, while others, such as meat and sugar, could be found only on the black market. The large landowners took advantage, appropriating crops that were destined for storage and reselling them on the black market. Allied bombardments sapped civilian morale. On 3 September 1943, British and Canadian troops of the Eighth Army landed in Calabria in Operation Baytown, the first time that the Allies landed on the Italian mainland. Those landings were a feint and the main Allied blow came on 8 September 1943 with the landing of the American 5th Army at Salerno in Campania that was intended to cut off Mezzogiorno Axis forces. The Germans anticipated the Allies' plan, and as a consequence, relatively little fighting came in Calabria. Calabria troops mostly surrendered to the advancing British 5th Infantry Division and 1st Canadian Division; relatively few German forces were present. The main obstacle was the trail of destruction left by German combat engineers who systematically blew up bridges and destroyed roads and railroads as the Wehrmacht retreated north. On the day of the American landing, General Dwight Eisenhower announced on the radio that the Armistice of Cassibile had been signed on 3 September, ending all Italian resistance.

The American Expedition (1799–1804) was a scientific exploration of Spanish America conducted by the Prussian naturalist Alexander von Humboldt and the French botanist Aimé Bonpland. Over the course of five years, the expedition traversed across present-day Venezuela, Colombia, Ecuador, Peru, Cuba, Mexico, and parts of the United States. Humboldt and Bonpland conducted pioneering research in fields including geography, biology, geology, meteorology, and ethnography. They observed and described vast regions of South and Central America, mapping rivers like the Orinoco and investigating the Andes Mountains—including an attempt to climb Chimborazo, accompanied by local savants and informants. Their observations of plant and animal life, atmospheric phenomena, and indigenous cultures - influenced by the debates ongoing in Spanish American in those years - laid the foundations for modern biogeography and ecology.

== Pharmacokinetics == Citicoline is water-soluble, with more than 90% oral bioavailability. Plasma levels of citicholine peak one hour after oral ingestion, and a majority of the citicoline is excreted as CO2 in respiration with the remaining citicoline being excreted through urine. The pharmacokinetic profile of citicholine cannot be described by a single smooth exponential decrease over time. However, the elimination half-life for citicholine has been reported as approximately 50 hours for citicholine removed via respiration and approximately 70 hours for citicholine removed via urine. Plasma levels of choline peak about four hours after ingestion.

=== Brand endorsement === Morea has also been engaged as a brand ambassador to represent sport leagues, charity organizations, and Indian states. He has endorsed prominent brands including Bisleri Vedica, 7 Up, Close up, Colgate Fresh, Live (in), Calida, Lakmé, Siyaram, Hero Honda CBZ, Monte Carlo and Chronotech. In May 2008, Dino Morea signed up as the brand ambassador for Bangalore Marathon. In September 2009, he became the brand ambassador of Goa Pro Soccer League.

Radioactive decay results in a reduction of summed rest mass, once the released energy (the disintegration energy) has escaped in some way. Although decay energy is sometimes defined as associated with the difference between the mass of the parent nuclide products and the mass of the decay products, this is true only of rest mass measurements, where some energy has been removed from the product system. This is true because the decay energy must always carry mass with it, wherever it appears (see mass in special relativity) according to the formula E = mc2. The decay energy is initially released as the energy of emitted photons plus the kinetic energy of massive emitted particles (that is, particles that have rest mass). If these particles come to thermal equilibrium with their surroundings and photons are absorbed, then the decay energy is transformed to thermal energy, which retains its mass. Decay energy, therefore, remains associated with a certain measure of the mass of the decay system, called invariant mass, which does not change during the decay, even though the energy of decay is distributed among decay particles. The energy of photons, the kinetic energy of emitted particles, and, later, the thermal energy of the surrounding matter, all contribute to the invariant mass of the system. Thus, while the sum of the rest masses of the particles is not conserved in radioactive decay, the system mass and system invariant mass (and also the system total energy) is conserved throughout any decay process.

Sources: en.wikipedia.org

Frequently asked questions

What distinguishes CJC-1295 from natural GHRH?

The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.

Why does the DAC group matter?

The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.

Is CJC-1295 an approved medicine?

It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

Network